The landscape of mitophagy in sepsis reveals PHB1 as an NLRP3 inflammasome inhibitor

Mitophagy is a selective autophagy targeting damaged and potential cytotoxic mitochondria, which can effectively prevent excessive cytotoxic production from damaged mitochondria and alleviate the inflammatory response. However, the potential role of mitophagy in sepsis remains poorly explored. Here, we studied the role of mitophagy in sepsis and its immune heterogeneity. By performing mitophagy-related typing on 348 sepsis samples, three clusters (A, B, and C) were obtained. Cluster A had the highest degree of mitophagy accompanied by lowest disease severity, while cluster C had the lowest degree of mitophagy with the highest disease severity. The three clusters had unique immune characteristics. We further revealed that the expression of PHB1 in these three clusters was significantly different and negatively correlated with the severity of sepsis, suggesting that PHB1 was involved in the development of sepsis. It has been reported that impaired mitophagy leads to the over-activation of inflammasomes, which promotes sepsis development. Further analysis showed that the expressions of NLRP3 inflammasomes core genes in cluster C were significantly up-regulated and negatively correlated with PHB1. Next, we verified whether PHB1 downregulation caused the activation of inflammasomes and found that the PHB1 knockdown increased the levels of mtDNA in the cytoplasm and enhanced the activation of NLRP3 inflammasomes. In addition, mitophagy inhibitor treatment abolished PHB1 knockdown-mediated activation of NLRP3 inflammasomes, suggesting that PHB1 inhibited the activation of inflammasomes through mitophagy. In conclusion, this study reveals that a high degree of mitophagy may predict a good outcome of sepsis, and PHB1 is a key NLRP3 inflammasome regulator via mitophagy in inflammatory diseases such as sepsis.

[1]  Nadezhda T. Doncheva,et al.  The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest , 2022, Nucleic Acids Res..

[2]  Huacai Zhang,et al.  Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options , 2022, Military Medical Research.

[3]  J. Timsit,et al.  Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development , 2022, Expert opinion on investigational drugs.

[4]  G. Berry,et al.  The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages , 2022, Nature Metabolism.

[5]  Ningning Li,et al.  Structural insights into the membrane microdomain organization by SPFH family proteins , 2022, Cell Research.

[6]  Andy Y. An,et al.  Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures , 2022, EBioMedicine.

[7]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[8]  K. K. Mahapatra,et al.  Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics. , 2021, The international journal of biochemistry & cell biology.

[9]  Melissa F. Adasme,et al.  PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA , 2021, Nucleic Acids Res..

[10]  Shakir Ali,et al.  The Role of Mitophagy in Pulmonary Sepsis. , 2021, Mitochondrion.

[11]  T. Kanneganti,et al.  NLRP3 inflammasome in cancer and metabolic diseases , 2021, Nature Immunology.

[12]  Koji Yamano,et al.  Molecular mechanisms and physiological functions of mitophagy , 2021, The EMBO journal.

[13]  Yang Liu,et al.  Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis , 2021, Theranostics.

[14]  Dongqiang Zeng,et al.  IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures , 2020, bioRxiv.

[15]  K. K. Mahapatra,et al.  The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. , 2020, Seminars in cancer biology.

[16]  D. Ji,et al.  FUN14 domain-containing 1-mediated mitophagy suppresses interleukin-1β production in macrophages. , 2020, International immunopharmacology.

[17]  Pengcheng Jiang,et al.  PINK1-mediated mitophagy protects against hepatic ischemia/reperfusion injury by restraining NLRP3 inflammasome activation. , 2020, Free radical biology & medicine.

[18]  M. Shankar-Hari,et al.  ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[19]  B. Allegranzi,et al.  Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis , 2020, Intensive Care Medicine.

[20]  E. Elinav,et al.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms , 2020, Cell Discovery.

[21]  W. Ding,et al.  Role and Mechanisms of Mitophagy in Liver Diseases , 2020, Cells.

[22]  K. Rajalingam,et al.  Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases , 2020, Cellular and Molecular Life Sciences.

[23]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[24]  I. Ganley,et al.  Outstanding Questions in Mitophagy: What we Do and Do Not Know. , 2020, Journal of molecular biology.

[25]  F. Petronilho,et al.  The NLRP3 Inflammasome and Its Role in Sepsis Development , 2019, Inflammation.

[26]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[27]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[28]  Domenico de Rasmo,et al.  Prohibitins: A Critical Role in Mitochondrial Functions and Implication in Diseases , 2019, Cells.

[29]  H. Prescott,et al.  Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis , 2018, Front. Immunol..

[30]  Nektarios Tavernarakis,et al.  Mechanisms of mitophagy in cellular homeostasis, physiology and pathology , 2018, Nature Cell Biology.

[31]  Geetanjali Dang,et al.  Severe sepsis and cardiac arrhythmias. , 2018, Annals of translational medicine.

[32]  Shaohui Huang,et al.  Mitophagy Contributes to the Pathogenesis of Inflammatory Diseases , 2018, Inflammation.

[33]  Nektarios Tavernarakis,et al.  The Role of Mitophagy in Innate Immunity , 2018, Front. Immunol..

[34]  D. Heffernan,et al.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis , 2018, Journal of leukocyte biology.

[35]  X. Guan,et al.  Thymosin alpha 1 treatment for patients with sepsis , 2018, Expert opinion on biological therapy.

[36]  R. Youle,et al.  Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance , 2018, Current Biology.

[37]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[38]  B. Wan,et al.  Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta‐analysis of Chinese and Indian patients☆,☆☆ , 2017, Journal of critical care.

[39]  L. Galluzzi,et al.  Autophagy and Mitophagy in Cardiovascular Disease. , 2017, Circulation research.

[40]  M. Z. Cader,et al.  Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms , 2017, Trends in Neurosciences.

[41]  Prashant Mishra,et al.  Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor , 2017, Cell.

[42]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[43]  J. Lieberman,et al.  Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores , 2016, Nature.

[44]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[45]  Dong Han,et al.  Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis. , 2015, International immunopharmacology.

[46]  Chuan-Qi Zhong,et al.  Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion , 2015, Cell Research.

[47]  Chee Keong Kwoh,et al.  Fast, accurate, and reliable molecular docking with QuickVina 2 , 2015, Bioinform..

[48]  F. Sutterwala,et al.  Initiation and perpetuation of NLRP3 inflammasome activation and assembly , 2015, Immunological reviews.

[49]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[50]  Jiujiu Yu,et al.  Inflammasome activation leads to Caspase-1–dependent mitochondrial damage and block of mitophagy , 2014, Proceedings of the National Academy of Sciences.

[51]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[52]  Katherine A. Fitzgerald,et al.  Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes , 2014, Cell.

[53]  D. Klionsky,et al.  The machinery of macroautophagy , 2013, Cell Research.

[54]  Y. Ohsumi.  Historical landmarks of autophagy research , 2013, Cell Research.

[55]  D. Klionsky,et al.  SnapShot: Selective Autophagy , 2013, Cell.

[56]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[57]  T. Calandra,et al.  Sepsis studies need new direction. , 2012, The Lancet. Infectious diseases.

[58]  Richard A. Flavell,et al.  Inflammasomes in health and disease , 2012, Nature.

[59]  Derek C Angus,et al.  The search for effective therapy for sepsis: back to the drawing board? , 2011, JAMA.

[60]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[61]  T. Langer,et al.  Prohibitins and the functional compartmentalization of mitochondrial membranes , 2009, Journal of Cell Science.

[62]  Nektarios Tavernarakis,et al.  Prohibitin and mitochondrial biology , 2009, Trends in Endocrinology & Metabolism.

[63]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[64]  Z. Ye,et al.  Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling , 2007, Proceedings of the National Academy of Sciences.

[65]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  T. Langer,et al.  Formation of membrane-bound ring complexes by prohibitins in mitochondria. , 2004, Molecular biology of the cell.

[67]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[68]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[69]  G. Decavalas,et al.  Severe Sepsis and Septic Shock , 2018 .

[70]  T. Langer,et al.  Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. , 2009, Biochimica et biophysica acta.